BICO Group

BICO Group
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Founded in 2016, BICO (formerly CELLINK) is the leading Bio Convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda

Wed, Mar 31, 2021 15:00 CET

CELLINK invites investors, analysts, shareholders, and media to a digital Capital Markets Day (CMD) on Wednesday May 12, 2021 at 2-5pm (CEST).We are the frontrunners in the evolving life science universe where we together with our customers develop game-changing solutions by combining biology and technology through our agenda for bioconvergence. CELLINK creates the future of medicine by providing technologies, products, and services for our customers to create, understand and master biology. Please join us during our CMD and explore our bioconvergence agenda, get to know our business

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Links

Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda